Prognostic significance of polyvascular disease in heart failure with preserved left ventricular ejection fraction
- PMID: 31305390
- PMCID: PMC6641821
- DOI: 10.1097/MD.0000000000015959
Prognostic significance of polyvascular disease in heart failure with preserved left ventricular ejection fraction
Abstract
The prognostic significance of systemic atherothrombosis in heart failure (HF) with preserved ejection fraction (HFpEF) remains unclear. This study aimed to investigate the relation between the presence of polyvascular disease (PVD) and cardiovascular outcomes in HFpEF patients.A total of 510 consecutive HFpEF patients were prospectively observed for up to 1500 days or until occurrence of cardiovascular events. PVD was defined as ≥2 coexistence of coronary artery disease, peripheral arterial disease, and cerebrovascular disease.Overall, 124 cardiovascular events were observed during follow-up (median: 1430 days). Kaplan-Meier curve showed HFpEF with PVD (n = 84) experienced more cardiovascular events than did those without PVD patients (44.0% vs 20.4%, log-rank: P < .001). Multivariable Cox proportional hazards analysis with significant factors from univariate analysis showed the presence of PVD (hazard ratio [HR]: 2.875, 95% [CI]: 1.894-4.365, P < .001), previous HF hospitalization (HR: 1.578, 95% CI: 1.031-2.414, P = .036), hemoglobin (HR: 0.889, 95% CI: 0.805-0.983, P = .021), serum sodium (HR: 0.946, 95% CI 0.896-1.000, P = .048), ln-BNP (per 1.0, HR: 1.255, 95% CI: 1.055-1.494, P = .010), and E/e' (HR: 1.047, 95% CI: 1.020-1.075, P < .001) significantly predicted future cardiovascular events. Multivariable Cox hazard analysis with 4 established factors (age, BNP, diabetes mellitus, and previous HF hospitalization) from the I-PRESERVE (Irbesartan in HFpEF) study showed PVD was independently associated with cardiovascular events in HFpEF patients (HR: 2.562, 95% CI: 1.715-3.827, P < .001).The presence of PVD is significantly associated with cardiovascular events in HFpEF, suggesting the importance of screening PVD in HFpEF.
Conflict of interest statement
The authors report no conflicts of interest.
Figures


Similar articles
-
Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction.J Am Coll Cardiol. 2012 Oct 30;60(18):1778-86. doi: 10.1016/j.jacc.2012.07.036. Epub 2012 Oct 3. J Am Coll Cardiol. 2012. PMID: 23040568
-
Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.J Am Coll Cardiol. 2019 Dec 10;74(23):2858-2873. doi: 10.1016/j.jacc.2019.09.063. J Am Coll Cardiol. 2019. PMID: 31806129 Clinical Trial.
-
Ankle-brachial index and incident heart failure with reduced versus preserved ejection fraction: The Multi-Ethnic Study of Atherosclerosis.Vasc Med. 2019 Dec;24(6):501-510. doi: 10.1177/1358863X19870602. Epub 2019 Sep 4. Vasc Med. 2019. PMID: 31480898
-
[Multidistrict atherosclerotic disease: epidemiological and clinical framework].G Ital Cardiol (Rome). 2024 Apr;25(4):239-251. doi: 10.1714/4244.42205. G Ital Cardiol (Rome). 2024. PMID: 38526360 Review. Italian.
-
Heart failure therapy in patients with coronary artery disease.Curr Opin Pharmacol. 2013 Apr;13(2):205-9. doi: 10.1016/j.coph.2013.01.009. Epub 2013 Mar 26. Curr Opin Pharmacol. 2013. PMID: 23540585 Review.
Cited by
-
Influence of polyvascular disease on clinical outcome in patients undergoing transcatheter aortic valve implantation via transfemoral access.PLoS One. 2021 Dec 2;16(12):e0260385. doi: 10.1371/journal.pone.0260385. eCollection 2021. PLoS One. 2021. PMID: 34855791 Free PMC article.
-
Beyond weight loss: the potential of glucagon-like peptide-1 receptor agonists for treating heart failure with preserved ejection fraction.Heart Fail Rev. 2025 Jan;30(1):17-38. doi: 10.1007/s10741-024-10438-2. Epub 2024 Sep 13. Heart Fail Rev. 2025. PMID: 39269643 Review.
-
Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment.Curr Cardiol Rep. 2024 Jun;26(6):505-520. doi: 10.1007/s11886-024-02063-0. Epub 2024 May 14. Curr Cardiol Rep. 2024. PMID: 38743352 Review.
-
The controlling nutritional status score predicts outcomes of cardiovascular events in patients with heart failure with preserved ejection fraction.Int J Cardiol Heart Vasc. 2020 Jun 26;29:100563. doi: 10.1016/j.ijcha.2020.100563. eCollection 2020 Aug. Int J Cardiol Heart Vasc. 2020. PMID: 32637567 Free PMC article.
-
Polyvascular atherosclerosis and renal dysfunction increase the odds of cognitive impairment in vascular disease: findings of the LipidCardio study.Eur J Med Res. 2024 Feb 22;29(1):141. doi: 10.1186/s40001-024-01734-6. Eur J Med Res. 2024. PMID: 38388510 Free PMC article.
References
-
- Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260–9. - PubMed
-
- Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011;4:27–35. - PubMed
-
- Tokitsu T, Yamamoto E, Hirata Y, et al. Clinical significance of pulse pressure in patients with heart failure with preserved left ventricular ejection fraction. Eur J Heart Fail 2016;18:1353–61. - PubMed
-
- Tokitsu T, Yamamoto E, Oike F, et al. Clinical significance of brachial-ankle pulse-wave velocity in patients with heart failure with preserved left ventricular ejection fraction. J Hypertens 2018;36:560–8. - PubMed
-
- Maeda H, Sugiyama S, Jinnouchi H, et al. Advanced peripheral microvascular endothelial dysfunction and polyvascular disease in patients with high cardiovascular risk. J Cardiol 2016;67:455–62. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous